OBJECTIVE: To describe the clinical epidemiology of HIV-associated end-stage renal failure (HIV/ESRF) from 1998 to 2007 in the United Kingdom. DESIGN: Observational cohort study. SETTING: Seven leading HIV centres and affiliated renal clinics in the United Kingdom. PARTICIPANTS: A total of 21 951 patients in whom renal function was measured. MAIN OUTCOME MEASURE: Development of end-stage renal failure (ESRF) as defined by initiation of permanent renal replacement therapy (pRRT). RESULTS: Sixty-eight (0.31%) patients had HIV/ESRF, 44 (64.7%) of whom were black. The prevalence of ESRF in black patients increased over time from 0.26% in 1998-1999 to 0.92% in 2006-2007 (P for trend = 0.001). Overall 5-year survival from starting pRRT was 70.3%, and significantly better for black patients compared to those of other ethnicities (85.2 vs. 43.4%, P = 0.001). In multivariable analysis, black ethnicity was associated with a higher risk of ESRF [HR 6.93, 95% confidence interval (CI) 3.56, 13.48], whereas a higher current CD4 cell count was associated with reduced risk (HR: 0.83, 95% CI 0.76, 0.95) per 50 cells higher). No association was seen between current viral load or current highly active antiretroviral therapy (HAART) status and ESRF. On the basis of these observations, we estimate that 231 HIV-infected patients required pRRT in the United Kingdom in 2007, and an HIV prevalence of 0.51% among the United Kingdom pRRT recipients in that year. CONCLUSION: The prevalence of HIV/ESRF increased during the HAART era to reach nearly 1% in black patients, in whom favourable survival rates were observed. Earlier HIV diagnosis will be an important strategy to stem the rising trend of HIV/ESRF.
OBJECTIVE: To describe the clinical epidemiology of HIV-associated end-stage renal failure (HIV/ESRF) from 1998 to 2007 in the United Kingdom. DESIGN: Observational cohort study. SETTING: Seven leading HIV centres and affiliated renal clinics in the United Kingdom. PARTICIPANTS: A total of 21 951 patients in whom renal function was measured. MAIN OUTCOME MEASURE: Development of end-stage renal failure (ESRF) as defined by initiation of permanent renal replacement therapy (pRRT). RESULTS: Sixty-eight (0.31%) patients had HIV/ESRF, 44 (64.7%) of whom were black. The prevalence of ESRF in black patients increased over time from 0.26% in 1998-1999 to 0.92% in 2006-2007 (P for trend = 0.001). Overall 5-year survival from starting pRRT was 70.3%, and significantly better for black patients compared to those of other ethnicities (85.2 vs. 43.4%, P = 0.001). In multivariable analysis, black ethnicity was associated with a higher risk of ESRF [HR 6.93, 95% confidence interval (CI) 3.56, 13.48], whereas a higher current CD4 cell count was associated with reduced risk (HR: 0.83, 95% CI 0.76, 0.95) per 50 cells higher). No association was seen between current viral load or current highly active antiretroviral therapy (HAART) status and ESRF. On the basis of these observations, we estimate that 231 HIV-infectedpatients required pRRT in the United Kingdom in 2007, and an HIV prevalence of 0.51% among the United Kingdom pRRT recipients in that year. CONCLUSION: The prevalence of HIV/ESRF increased during the HAART era to reach nearly 1% in black patients, in whom favourable survival rates were observed. Earlier HIV diagnosis will be an important strategy to stem the rising trend of HIV/ESRF.
Authors: Jason Cheung; Rainer Puhr; Kathy Petoumenos; David A Cooper; Ian Woolley; Manoji Gunathilake; Nigel Raymond; Rick Varma; Catherine C O'Connor; David M Gracey Journal: Nephrology (Carlton) Date: 2018-08 Impact factor: 2.506
Authors: Alison G Abraham; Keri N Althoff; Yuezhou Jing; Michelle M Estrella; Mari M Kitahata; C William Wester; Ronald J Bosch; Heidi Crane; Joseph Eron; M John Gill; Michael A Horberg; Amy C Justice; Marina Klein; Angel M Mayor; Richard D Moore; Frank J Palella; Chirag R Parikh; Michael J Silverberg; Elizabeth T Golub; Lisa P Jacobson; Sonia Napravnik; Gregory M Lucas Journal: Clin Infect Dis Date: 2014-11-18 Impact factor: 9.079
Authors: Fowzia Ibrahim; Lisa Hamzah; Rachael Jones; Dorothea Nitsch; Caroline Sabin; Frank A Post Journal: Am J Kidney Dis Date: 2012-04-21 Impact factor: 8.860
Authors: Sophie Jose; Lisa Hamzah; Rachael Jones; Debbie Williams; Alan Winston; Fiona Burns; Andrew N Phillips; Caroline A Sabin; Frank A Post Journal: J Infect Dis Date: 2018-10-20 Impact factor: 5.226
Authors: Rachel K Y Hung; Beatriz Santana-Suarez; Elizabeth Binns-Roemer; Lucy Campbell; Kate Bramham; Lisa Hamzah; Julie Fox; James E Burns; Amanda Clarke; Rachel Vincent; Rachael Jones; David A Price; Denis Onyango; Mark Harber; Rachel Hilton; John W Booth; Caroline A Sabin; Cheryl A Winkler; Frank A Post Journal: EClinicalMedicine Date: 2021-07-08
Authors: Lucy J Campbell; Tracy Dew; Rashim Salota; Emily Cheserem; Lisa Hamzah; Fowzia Ibrahim; Pantelis A Sarafidis; Caje F Moniz; Bruce M Hendry; Mary Poulton; Roy A Sherwood; Frank A Post Journal: BMC Nephrol Date: 2012-08-10 Impact factor: 2.388